5-(4-Chlorobutyl)-1-cyclohexyl-1H-tetrazole (CAS 73963-42-5) is a pharma-grade heterocyclic intermediate used for the construction of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, the active moiety of cilostazol. The molecular formula is C₁₁H₁₉ClN₄, and the molar mass is 242.75 g/mol. The product is supplied as the free base, not as a hydrochloride or quaternary salt. Because no USP or Ph. Eur. monograph exists for this specific intermediate, procurement documentation identifies the material by its CAS registry number, chemical name, and supplier-specific grade code rather than by a compendial model number. The descriptor “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” refers to the grade of the material and the dosage forms of the final cilostazol drug product after chemical conversion; the intermediate itself is not dosed directly.

Typical pharma-grade lots are specified as white to off-white crystalline powder. Because residual solvent composition can shift the solid-liquid transition, melting behavior is not treated as a single compendial constant, and published data for this specific configuration is limited. Water content is controlled because the terminal primary chloride can hydrolyze to the corresponding alcohol, generating 5-(4-hydroxybutyl)-1-cyclohexyl-1H-tetrazole as a process impurity. The material is dried in a vacuum tray dryer at 35–40°C under 10–20 kPa absolute to avoid HCl elimination; higher temperatures promote formation of the unsaturated butenyl analog. Solubility is routinely characterized in dichloromethane and acetone for reaction charging; aqueous solubility is low, and the compound is not supplied as a pre-dissolved oral liquid. The product is packed in double polyethylene liners inside a fiberboard drum under nitrogen, with a moisture-resistant seal.

Regulatory classification under ICH Q7 is an important distinction. If the applicant designates this chlorobutyl tetrazole as an API starting material, the GMP requirements under ICH Q7 Sections 1.3 and 5 apply from that step forward. If it is used before the designated starting material, the same quality controls may still be applied because the chlorine-bearing chain directly determines the structure of the final butoxy linker. The product grade is therefore qualified for multiple filing strategies; batch records include the supplier’s synthetic pathway and residual solvent profile to support both starting material and intermediate status.

What Impurity Profiles Separate Pharma-Grade Material from Technical-Grade 5-(4-Chlorobutyl)-1-Cyclohexyl Tetrazole?

The primary separation is not parent peak area; technical-grade material may still show an HPLC area percent above 98%. Pharma-grade material is specified by the controlled profile of process-related impurities that can survive the final cilostazol synthesis. Residual 1,4-dichlorobutane is the most significant volatile alkylating agent and is monitored by headspace gas chromatography with flame ionization detection on a DB-624 or equivalent low-polarity capillary column. The limit is aligned with ICH Q3C(R8) residual solvent guidance where the solvent is classified; because the compound may pose a genotoxic impurity risk, additional purge-factor data are required under ICH M7(R1) when the intermediate is introduced late in the API synthesis. The tetrazole ring has a weak chromophore, so HPLC purity is typically performed at 210 nm with mobile-phase degassing and high-purity acetonitrile; this low-wavelength detection increases sensitivity but requires strict mobile phase cleanliness to control baseline drift. Individual unspecified impurities are generally controlled to ≤0.10% and total impurities to ≤0.50% in pharma-grade lots to preserve the purification capacity of the final cilostazol crystallization.

Elemental impurities are measured by inductively coupled plasma mass spectrometry after closed-vessel microwave digestion. The elements of interest are those expected from the synthetic route: palladium if catalytic reduction is used in tetrazole formation, copper or iron from reactor corrosion, and zinc from any Lewis acid step. Limits are assigned using ICH Q3D consideration for the final maximum daily dose of cilostazol, not the intermediate alone. For injectable dosage forms, the final API is also tested for endotoxin and particulate matter using USP 85 and USP 788, respectively; these tests are not normally performed on the intermediate because it is not sterile and is converted in organic solvent.

Specification Architecture and Analytical Control Strategy

The release specification is structured to address three failure modes: hydrolytic conversion of the terminal chloride, retention of the alkylating agent, and carryover of inorganic residues that would affect final API conductivity or endotoxin control. Analytical methods follow pharmacopoeial general chapters where applicable, but the acceptance criteria are supplier-specific because no monograph is published. The table below lists representative attributes for pharma-grade material; lot-specific certificates of analysis take precedence and may differ in method conditions depending on the manufacturer’s validated procedure.

Analytical method transfer for HPLC includes verification of linearity over 0.05–1.50 mg/mL and spike recovery of the unsaturated impurity at 0.05%, 0.10%, and 0.15%. The limit of quantitation for the unsaturated analog is typically set at 0.03% area. System suitability requires tailing factor ≤2.0 and resolution ≥2.0 between the tetrazole parent and the nearest specified impurity. These values are not monograph criteria; they are common validation acceptance ranges used in method transfer protocols.

Residual 1,4-Dichlorobutane Is the Primary Purge Marker

Residual 1,4-dichlorobutane is used as the main process marker because it is the immediate alkylating agent from the tetrazole formation step and can act as a potential genotoxic impurity. Control of this marker at ≤0.10% does not by itself demonstrate safety; the manufacturer is expected to provide purge data showing its fate through the O-alkylation, workup, and crystallization of final cilostazol API. In production-scale campaigns, the marker is measured on a headspace GC calibrated with a validated standard at 0.05–0.20%. Column performance is monitored by resolution between 1,4-dichlorobutane and the process solvent peaks; a DB-624 column with a 30 m length, 0.32 mm internal diameter, and 1.8 µm film thickness is typical. If purge data are incomplete, the applicant may need to set a tighter limit or introduce a cleaning step before final API crystallization.

At production scale, batch-to-batch variance in residual 1,4-dichlorobutane is often tied to the efficiency of the water-wash step after tetrazole formation. If the wash is incomplete, the reactor headspace shows a sharp increase in the marker and the final API may fail the alkylating agent control. Glass-lined reactors with spray-ball cleaning are therefore used between campaigns, and the product is sampled at three levels of the holding tank to check for stratification.

When the Intermediate Is Charged into Cilostazol API Synthesis, Process Parameters Shift

In the final O-alkylation, 6-hydroxy-3,4-dihydro-2(1H)-quinolinone is combined with the chlorobutyl tetrazole in a polar aprotic solvent, typically dimethylformamide or acetone, with potassium carbonate as the acid scavenger. The reaction is run in a glass-lined reactor with overhead stirring, reflux condenser, and nitrogen blanketing; at pilot scale, a 500 L glass-lined reactor with bottom discharge is common. Because the chloro leaving group is less reactive than the corresponding bromo analog, the process may require 70–80°C in acetone or 8–12 h in dimethylformamide at 60–80°C to reach endpoint; published data for a universal endpoint is limited. The critical impurity risk is HCl elimination to form 5-(but-3-enyl)-1-cyclohexyl-1H-tetrazole. This unsaturated byproduct can carry through to the final API unless the cilostazol crystallization solvent and cooling rate are selected to purge it. Process development therefore tracks the unsaturated impurity at a reporting threshold of 0.05% in both intermediate and final API.

Post-reaction workup includes water quenching and phase separation in a vertical decanter. The organic phase is washed with dilute sodium hydroxide to remove unreacted phenol and then with water until neutral pH. The clarified organic phase is concentrated in a wiped-film evaporator at 45–50°C and 5–10 kPa to a target residue. The intermediate is not isolated as a final API; it is immediately carried forward or stored under nitrogen if the next step is run in a different campaign.

The downstream cilostazol API produced from this intermediate is intended for oral tablet, capsule, granule, and injectable product development. In tablet and capsule manufacturing, the final API is blended with excipients and processed by direct compression or high-shear granulation; the intermediate does not appear in the dosage form. For oral granules, particle size distribution and flowability of the final API are relevant, not the intermediate. Injectable formulations require the final API to meet higher bioburden, endotoxin, and particulate limits; the intermediate therefore must not introduce insoluble inorganic residues or pyrogenic contamination that survive purification.

Chlorobutyl Versus Bromobutyl and Hydroxybutyl Analogues in O-Alkylation

The chloro intermediate is preferred over the bromobutyl analog because the lower leaving-group reactivity reduces uncontrolled dialkylation and residual bromide contamination. The bromo analog reacts faster but produces a more aggressive alkylating stream and can leave inorganic bromide residues that are difficult to purge in the final API. The hydroxybutyl analog is not directly suitable because the hydroxyl group must be converted to a leaving group; this activation step introduces additional impurities and is controlled only under anhydrous conditions. The correct regioisomer is the 1-substituted tetrazole; the 2H-tetrazole regioisomer, if present, can carry through as a structural isomer of cilostazol and must be controlled by polarity-based chromatography because it has different retention behavior but may have similar mass spectrometric fragmentation.

The 2H-tetrazole regioisomer is best detected by ¹H NMR because the methylene protons adjacent to the tetrazole ring show a different coupling pattern. In HPLC, the regioisomer may co-elute with the parent under isocratic conditions unless a polar embedded column is used. A limit of 0.10–0.50% is often applied to the regioisomer in the intermediate because the final cilostazol crystallization supplies only a limited additional purge.

Stability testing is conducted under ICH Q1A(R2) conditions for packaging and shipment. The product is stored at 2–8°C in a dry, nitrogen-blanketed container. At ambient relative humidity above 60%, the powder can adsorb moisture and undergo surface hydrolysis; drums should be resealed immediately after sampling. A retest period of 24 months is common for material supplied with the above specification, provided the storage temperature remains below 8°C; published stability data for this specific configuration is limited, and the supplier CoA should be consulted for the assigned retest date.